4D Molecular Therapeutics FDMT Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's change in accrued liabilities?
- 4D Molecular Therapeutics (FDMT) reported change in accrued liabilities of -$4.12M in Q1 2026.
- How has 4D Molecular Therapeutics's change in accrued liabilities changed year-over-year?
- 4D Molecular Therapeutics's change in accrued liabilities decreased by 78.3% year-over-year, from -$2.31M to -$4.12M.
- What is the long-term trend for 4D Molecular Therapeutics's change in accrued liabilities?
- Over 3 years (2021 to 2025), 4D Molecular Therapeutics's change in accrued liabilities has grown at a 127.9% compound annual growth rate (CAGR), from $689K to $8.15M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.